Loading…
the sparker alert will let you know when a significant move starts with an audio alert, so You'll never miss an Opportunity.
Celcuity Inc Is A Clinical-Stage Biotechnology Company Developing Targeted Therapies For Multiple Solid Tumors. Its Candidate, Gedatolisib, Is A Kinase Inhibitor Of The Pi3k/Akt/Mtor (Pam) Pathway, Binding All Class I Pi3k Isoforms And Mtorc1/2, Offering Comprehensive Inhibition With A Mechanism And Pharmacokinetics Differentiated From Other Therapies. The Phase 3 Viktoria-1 Trial, Evaluating Gedatolisib With Fulvestrant, With Or Without Palbociclib, In Hr+/Her2- Breast Cancer, Has Completed Enrollment And Reported Results For Pik3ca Wt Tumors, With Cohort 2 (Pik3ca Mt) Also Enrolled. Phase 3 Viktoria-2 And Phase 1b/2 Celc-G-201 Trials, Evaluating Combinations In Endocrine-Resistant Hr+/Her2- Breast Cancer And Metastatic Castration-Resistant Prostate Cancer, Are Ongoing.